Search
News & Events
Young ambassadors keep researchers on their toesFlat out trying hard to keep up with the ever-changing threats from cyberbullying, The Kids Research Institute Australia counts itself fortunate to have youth on its side.
Research
The Early Years PartnershipThe Early Years Partnership is a 10-year (2018-2028) partnership between the WA State Government (Departments of Communities, Health, and Education), Minderoo Foundation and The Kids Research Institute Australia as the evidence and evaluation partner.
News & Events
The Kids Research Institute Australia researchers share in State Government science grantsFour The Kids Research Institute Australia researchers are among those who have received funding in the WA State Government's Merit Award Program announced today.
Research
Epidemiology of Otitis Media hospitalisations in Western Australia: a retrospective population cohort study (1996-2012)Deborah Hannah Lehmann Moore AO, MBBS, MSc OAM BSc (Hons) GradDipClinEpi PhD Honorary Emeritus Fellow Head, Infectious Diseases Research 08 6319 1427
Research
Evaluating the use and effectiveness of passive immunization in reducing RSV-associated morbidity in high risk infantsHannah Tom Moore Snelling OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Diseases Research Head, Infectious
Research
Optimising influenza vaccine uptake in children with medical comorbiditiesChristopher Hannah Blyth Moore MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers Centre of Vaccines and
Research
Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic studySince 1955, the recommended strategy for rheumatic heart disease secondary prophylaxis has been benzathine penicillin G injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration.
Research
Skin health of urban-living Aboriginal children attending a primary care Aboriginal Community Controlled Health Organisation clinicDespite increasing urbanisation, little is known about skin health for urban-living Aboriginal children and young people (CYP, aged <18 years). This study aimed to investigate the primary care burden and clinical characteristics of skin conditions in this cohort.